Tarsus Pharmaceuticals TARS
$73.01 −$4.66 (-6.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $71.00 -2.75%
Open$77.09
Prev close$77.67
Day range$72.57 – $78.11
Volume706.8K
Market cap$3.60B
P/E (TTM)–
Dividend yield–
TARS Stock News
Headlines matching Tarsus Pharmaceuticals or the TARS ticker, most recent first.
- Jefferies Initiates Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Announces Target Price $105
- Goldman Sachs Upgrades Tarsus Pharmaceuticals(TARS.US) to Buy Rating, Raises Target Price to $116 Positive
- Barclays Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $110 Positive
- LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104
- LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104 Positive
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 Positive
- H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $98
- William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100
- Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $100 Positive
- A Quick Look at Today's Ratings for Tarsus Pharmaceuticals(TARS.US), With a Forecast Between $88 to $100
- Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Prime Medicine, Inc. (PRME) and Ascendis Pharma (ASND)
- Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $98 Negative
- Guggenheim Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Cuts Target Price to $89 Negative
No comments yet — be the first to weigh in on TARS.
Sign in to join the discussion.